BioCentury
ARTICLE | Company News

Alnylam, Tekmira deal

June 13, 2011 7:00 AM UTC

Tekmira received rights from Alnylam to develop RNAi therapeutic targeting WEE1 tyrosine kinase (WEE1) and COP9 signalsome complex subunit 5 ( CSN5; COPS5; JAB1). Tekmira is conducting preclinical testing on WEE1/CSN5 product candidate formulations. Terms were not disclosed. ...